bg image


Cleaner and safer
open heart surgery

    Patients    Medical professionals    Investors


Improved surgical drainage systems are needed

The current standard of postoperative care in cardiac surgery entails an unnecessary high risk of excessive bleeding and acute cardiac tamponades. A wide spectrum of secondary complications is related to these conditions.

An important cause of these problems is the current use of imperfect and inaccurate wound drainage that make it necessary to develop and introduce to the market a breakthrough in postoperative surgical drainage technology. Reducing the risks after cardiac surgery will have a high impact on global health benefits and health care costs.


Making heart surgery safer.

Haermonics aims to deliver an economical alternative for postoperative drainage products in the cardiac surgery market. On top of the economic value Haermonics delivers a cost-effective high-end technology product (drainage and flushing system) that is capable of providing smart clinical decision support by controlling and analysing surgical blood loss.

Haermonics technology provides an integrated solution for surgical blood loss and wound healing, targeted versatile therapy, and smart integration within its complex working environment. The safety and ease that the Haermonics drainage technology has to offer will enable improved patient outcome after surgical procedures when compared to current standards.
bg image

Quote 1

Blood is our most
precious organ

“Isn’t it a shame we accept that each year millions of gallons of blood drain from critically ill people into waste bags?”
Dave Koolbergen



Breakthrough technology

Haermonics developed such a breakthrough technology: a drainage and flushing system that allows safe implementation of a new clinical working method called continuous postoperative pericardial flushing (CPPF). CPPF is based on the clinical observation of inventor Koolbergen that during re-exploration for postoperative bleeding, removal of accumulated blood and clots by solely flushing the pericardial space with a warm saline solution is enough to stop the bleeding instantly in a significant number of cases.

Driven by concerns about postoperative drainage issues, postoperative bleeding complications, cardiac tamponades, and the toxic effect of remaining blood and clots on surrounding tissues, Koolbergen and PhD candidate Manshanden of the Academic Medical Center (AMC) Amsterdam dedicated their research to come up with a clinically feasible concept for the use of CPPF. Haermonics technology allows controlled infusion of a warmed liquid solution into the pericardial cavity after the operation while the system monitors blood loss.

Continuous flushing will result in a lower viscosity mixture that will prevent chest tubes from clogging and promote the evacuation of blood and clots from the pericardial cavity. Haermonics’ drainage and flushing technology overcomes disadvantages of current surgical drainage technologies. Haermonics has patented its flushing device and disposables, WO2015086857, proved unique and patentable, EPO status in EU and patent approved in USA and China.

non cppfcppf

The Next Step


  • Prevent acute cardiac tamponades
  • Reduce the amount of blood transfused by 50%
  • Safe 8.000 ICU days and 13.000 hospital ward days a year
  • Save more than €30 million of medical expenses
  • Improve workflow of the medical professionals

The next step

For further development of the technology, Haermonics is looking to cooperate with medical centers globally to substantiate the CPPF method and investigate its future use for targeted therapy. Haermonics is also looking for partners to develop the current prototype into a commercially viable product.

The Team

Wouter Markus

Wouter Markus


David Koolbergen

David Koolbergen

Chief Medical Officer

Eva Diephuis

Eva Diephuis

Clinical Trials Coordinator

Luc Koch

Luc Koch


bg image

Quote 2

Effective Measurements

“On the other hand, when our surgery causes blood to leave the vascular system, blood becomes a highly toxic and injurious agent itself. Isn’t it strange that we do not take the necessary and effective measurements to definitively clean up our operation site from this?” Dave Koolbergen






Haermonics is well funded for the near future. Seriously interested future investors are kindly asked to fill in below form with specific questions. Haermonics is about saving lives. Quality and transparency are key to reach are goals. We strive for quality and transparency in our communication with investors and shareholders.

Head office

  • Head office
  • Microlab
  • Kastanjelaan 400
  • 5616 LZ Eindhoven
  • The Netherlands

Research office

  • Research office
  • Amsterdam University Medical Center
  • Department of Cardiothoracic Surgery
  • Meibergdreef 9
  • 1105 AZ Amsterdam
  • The Netherlands






MD squared
LifeTec Group
NPK Design